June 15, 2026

Dana-Farber Research News 06.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 16 - 31.

Dana-Farber

June 08, 2026

What the Biggest ASCO Cancer Research Updates Could Mean for Patients

Each year, the American Society of Clinical Oncology Annual Meeting brings together cancer specialists from around the world to share the research most likely to shape the next chapter of cancer care. This year’s major updates point to several important themes: more precise treatment, smarter use of surgery and chemotherapy, new approaches for difficult-to-treat cancers and a growing recognition that supportive care, including exercise, can be part of cancer treatment planning.

Baptist Health South Florida

June 02, 2026

ADC Provides Patients with Better Results Even After Subsequent Therapy for Advanced Triple-Negative Breast Cancer

A shift in the way advanced triple-negative breast cancer is treated may be on the horizon with mounting evidence that moving sacituzumab govitecan, an antibody-drug conjugate (ADC), to the first line of treatment confers long-term benefit compared to standard therapy, including continued benefit even after subsequent therapy.

Dana-Farber

May 26, 2026

New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

New guidance from the American College of Physicians (ACP) recommends biennial mammography screening for average-risk women ages 50 to 74.

Baptist Health South Florida

May 25, 2026

Roswell Park at ASCO 2026: GLP-1s and Aggressive Breast Cancer, CAR T in Older Adults, AI-Informed Benchmarking

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago

Roswell Park Comprehensive Cancer Center

May 15, 2026

Dana-Farber Research News 05.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 16 - 30.

Dana-Farber

May 13, 2026

Addressing Tamoxifen-Associated Weight Gain: Lifestyle and Pharmacotherapy Options

Tamoxifen is commonly prescribed in hormone receptor-positive breast cancer but also associated with weight gain, which can complicate survivorship care. This narrative review summarizes evidence on tamoxifen-associated weight gain and outlines pharmacologic weight management options in this population.

Jadpro

May 13, 2026

Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality

A new report released by the Union for International Cancer Control shows that people exposed over the long term to fine particulate matter (PM2.5) (such as vehicle exhaust, wildfires, wood burning) h...

The ASCO Post

May 13, 2026

The Impact of Physical Activity Levels on Sexual Function in Breast Cancer Survivors: An Integrative Review

Sexual dysfunction is a lasting effect of treatment and can impact the quality of life of breast cancer survivors. This review examined the impact of different levels (none/low, moderate, and high) of physical activity on sexual outcomes in breast cancer survivors.

Jadpro

May 12, 2026

Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade

A new study from Dana-Farber Cancer Institute shows that cases of stage IV breast cancer, a common but largely difficult to treat disease, are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published today JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly, from 9.5 cases per 100,000 women in 2010 to 11.2 cases per 100,000 women in 2021. Stage IV, or de novo metastatic breast cancer, refers to cancer has already spread to distant organs at the time initial diagnosis.

Dana-Farber